Julie Childers
Primary Care · Dublin, GANPI 1871138685
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations.
Across 127 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$393
- Regeneron Healthcare Solutions, Inc.$319
- AstraZeneca$263
- Boehringer Ingelheim$217
- GSK$198
- Actelion Pharmaceuticals US, Inc.$154
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,64697%
- Education$803%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 14 | $393 |
| Regeneron Healthcare Solutions, Inc. | 10 | $319 |
| AstraZeneca | 14 | $263 |
| Boehringer Ingelheim | 9 | $217 |
| GSK | 16 | $198 |
| Actelion Pharmaceuticals US, Inc. | 6 | $154 |
| Vanda Pharmaceuticals Inc. | 2 | $148 |
| Insmed, Inc. | 12 | $139 |
| Verona Pharma, Inc. | 4 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $104 |
| Baxter Healthcare | 3 | $104 |
| Amgen | 4 | $96 |
| Electromed, Inc. | 7 | $72 |
| Merck | 3 | $59 |
| Mylan Specialty L.p. | 3 | $48 |
| ANI Pharmaceuticals, Inc. | 2 | $48 |
| Grifols USA, LLC | 2 | $41 |
| Lilly USA, LLC | 2 | $40 |
| Harmony Biosciences LLC | 2 | $33 |
| Corcept Therapeutics | 1 | $29 |
| Viatris Specialty LLC | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Ambu Inc. | 1 | $18 |
| Novo Nordisk | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fanapt$125
How this compares
$2,726 in reported general payments places this provider in the 80th percentile of 235 primary care providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 135 | $103,568 |
| OzempicSemaglutide | 22 | $28,466 |
| RybelsusSemaglutide | 13 | $25,835 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $23,941 |
| JardianceEmpagliflozin | 19 | $23,087 |
| JanuviaSitagliptin Phosphate | 21 | $17,597 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $12,938 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $11,631 |
| Spiriva RespimatTiotropium Bromide | 18 | $9,439 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,512 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 196 | $4,260 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $2,922 |
| Famotidine | 146 | $2,851 |
| Montelukast Sodium | 229 | $1,947 |
| Fluticasone Propionate | 135 | $1,905 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $198 | $121,018170 claims |
| Novo NordiskOzempic, Rybelsus | $15 | $54,30035 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $263 | $35,57384 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $217 | $32,52637 claims |
| MerckJanuvia | $59 | $17,59721 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $48 | $54017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 235 primary care providers in Georgia.
Other primary care in Dublin
- Pamela TurkDouglas$15K
- Morgan JonesLawrenceville$14K
- Jessi HaleColumbus$13K
- Meredith CarrAugusta$12K
- Ashtyn ZaryckiSavannah$12K
- Zanetta BryantNewnan$11K
- Hannah CummingsSuwanee$9K
- Michelle LadewigGainesville$7K
- Lucia OcanoviciuCanton$7K
- Sarah NewGrovetown$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.